Oncotelic Therapeutics (OTLC) Stock Price, News & Analysis

Company Overview

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.

Key Stats

• Today's Range: $0.06 to $0.06
• 50-Day Range: $0.05 to $0.07
• 52-Week Range: $0.02 to $0.07
• Volume: 5,100 shs
• Average Volume: 113,233 shs
• Market Capitalization: $25.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OTLC Stock Analysis - Frequently Asked Questions

How have OTLC shares performed this year?

Oncotelic Therapeutics' stock was trading at $0.0350 at the beginning of the year. Since then, OTLC shares have increased by 78.6% and is now trading at $0.0625.
View the best growth stocks for 2025 here.

How were Oncotelic Therapeutics' earnings last quarter?

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) announced its quarterly earnings data on Thursday, August, 19th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.02.

How do I buy shares of Oncotelic Therapeutics?

Shares of OTLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Oncotelic Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncotelic Therapeutics investors own include MariMed (MRMD), First Wave BioPharma (FWBI), DSS (DSS), CEMEX (CX), CohBar (CWBR), ContraFect (CFRX) and Avid Bioservices (CDMO).

Company Calendar

• Last Earnings: 8/19/2021
• Today: 6/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:OTLC
• CIK: 908259
• Web: www.mateon.com
• Phone: (650) 635-7000
• Fax: 650-635-7001
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.90 million
• Net Margins: N/A
• Pretax Margin: -2,147.14%
• Return on Equity: -8.48%
• Return on Assets: -3.09%

Debt

• Debt-to-Equity Ratio: 0.28
• Current Ratio: 0.01
• Quick Ratio: 0.01

Sales & Book Value

• Annual Sales: $70 thousand
• Price / Sales: 364.55
• Cash Flow: $0.02 per share
• Price / Cash Flow: 3.12
• Book Value: $0.03 per share
• Price / Book: 2.08

Miscellaneous

• Outstanding Shares: 408,292,000
• Free Float: 246,931,000
• Market Cap: $25.52 million
• Optionable: Not Optionable
• Beta: -0.66